login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

ESC sets consensus over TAVI


Friday, 02 Sep 2011 12:33

 

The annual meeting of the European Society of Cardiology, in Paris, has enhanced the status of TAVI as the “gold standard” for inoperable patients suffering from severe aortic stenosis. However, concerns about high rates of permanent pacemaker implantation after TAVI remain, specialists say. 


TAVI was introduced nearly 10 years ago as an alternative procedure with limited application but it has expanded significantly in the course of recent years. Despite its increasing popularity among physicians, however, haemodynamic performance and valve durability remain unknown.


Now, for the first time, data from 393 consecutive patients undergoing implantation of a CoreValve self-expandable prosthesis at the German Heart Centre in Munich, Germany, have been presented: they show a “sustained improvement of haemodynamic values” and no signs of early or “unexpected” deterioration of the valve at three-year of follow-up.

 

“We all know that any biological valve gets deteriorated after a certain period of time, would this be 10 or 12 years. We know exactly when this will occur to a traditional heart valve, but we do not know when this will occur to a transcatheter valve. Now we know that after three years the haemodynamic performance of transcatheter valves is unchanged,” Anke Optiz, co-investigator of the study, told Cardiovascular News.

 

Based on the societies guidelines, so far most of the TAVI registries have included patients with high logistic Euroscore (20% or higher). However data presented at ESC this year suggest that 100% procedural success is possible even in a patient population with lower logistic Euroscore. The prospective, single-centre data refer to a cohort of 177 patients who underwent implantation with the Edwards valve at the Rouen University Hospital, France, between May 2006 and January 2011.

 

“We examined the population with lower logistic Euroscore because we were under the impression that these patients reacted better to TAVI as they were younger and had fewer comorbidities,” said Matthieu Godin, co-investigator of the study. “The retrospective analysis showed absence of death at 30 days for this specific group of low-risk patients. This result was beyond our expectations,” he added. Despite this data, Godin noted, “we should never forget that conventional surgery remains the gold standard for the lower-risk patient population”.

 

The Rouen experience is not isolated. An increasing trend to include lower risk patients into TAVI registries has been observed across European countries in the last few years. But according to both cardiology and cardiac surgery specialists discussing TAVI at ESC, this should not become standard practice.

 

“We can say that TAVI is doing relatively well – better than conventional surgery – within a certain high-risk group. But it is difficult to say that TAVI will necessarily do better in the lower group as well, because we do not have evidence of better results with TAVI compared to conventional surgery in any trial, including the US PARTNER trial where TAVI results are extremely good,” Olaf Wendler, clinical director, Cardiothoracic Surgery, King’s College Hospital, London, UK, told Cardiovascular News. “That is why I think TAVI should focus on patients who would clearly benefit from this new treatment immediately.”




Add New Comment

Related Items


Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

French hospital celebrates 30 years of implanting artificial hearts
Wednesday, 13 Apr 2016
La Pitié-Salpêtrière Hospital (Paris, France), the world’s leading artificial heart centre, is celebrating the 30th anniversary of the first Total Artificial Heart implantation. The centre has now ... French hospital celebrates 30 years of implanting artificial hearts

Tuesday, 05 Apr 2016
One-month, follow-up patient cohort data from the Revelution trial of Medtronic’s novel drug-filled stent indicate that device is associated with rapid vessel healing without inflammation, as ... Early data show good rapid healing for Medtronic’s investigational drug-filled stent

Features


Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy
Monday, 09 May 2016
According to Usman Baber, TWILIGHT is a unique and innovative study in that the experimental intervention is to withdraw rather than add to existing background pharmacotherapy. In this commentary, he ... Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy

The role of sutureless and rapid-deployment valves
Tuesday, 05 Apr 2016
Antonio Miceli explores the data for sutureless and rapid-deployment surgical valves for the management of patients with severe aortic stenosis. He also reviews the place of these new devices ... The role of sutureless and rapid-deployment valves

Profiles


Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions